US 8637004

US patent 8637004, titled "Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions," was filed on August 14, 2009, and issued on January 28, 2014. The current assignee is Mesoblast International SARL. The inventors are Alla Danilkovich, Robert E. Newman, JR., Samson Tom, Christopher Ton, Zhanling Wang, and Randell G. Young.

Abstract:
The patent discloses purified mesenchymal stem cell pharmaceutical compositions and methods of manufacturing them using centrifugal filtration. It also details threshold limits for the intravenous administration of mesenchymal stem cell pharmaceutical compositions containing residual animal products.

Plain-Language Overview of Independent Claims:

• Claim 1: This claims a pharmaceutically acceptable composition of purified mesenchymal stem cells (MSCs) where the amount of residual bovine serum albumin (BSA) is less than approximately 55 micrograms per milliliter (μg/mL). Additionally, the MSCs in this composition have a D90 (a measure of particle size distribution, indicating that 90% of the cells/aggregates are below this size) for aggregates between about 18 μm and 30 μm.

• Claim 10: This claim describes a pharmaceutically acceptable composition of purified MSCs that contains MSC aggregates with a D90 of less than approximately 150 μm. This composition also has residual BSA levels between about 8 μg/mL and 12 μg/mL, and the MSCs themselves exhibit a D90 between about 18 μm and 30 μm.

• Claim 11: This covers a method for preparing a purified MSC composition. The method involves four steps: (a) mixing MSCs (which initially contain some residual non-human serum) with a wash solution; (b) agitating this mixture; (c) separating the wash solution from the MSCs using centrifugal filtration; and (d) recovering the purified MSCs. The resulting composition must have less than about 55 μg/mL of residual non-human serum protein.

• Claim 19: Similar to Claim 11, this describes a method for preparing a purified MSC composition involving contacting, agitating, and separating using centrifugal filtration. The distinguishing feature is that the recovered purified MSCs form a composition where any mesenchymal stem cell aggregates present have a D90 of less than about 150 μm.

• Claim 23: This claim outlines a method for preparing a pharmaceutical MSC composition. It includes contacting MSCs with a wash solution, agitating the mixture, separating the wash solution via centrifugal filtration, and recovering purified MSCs. The recovered pharmaceutical composition must contain MSCs that exhibit a D90 between about 18 μm and 30 μm.

• Claim 29: This claim focuses on a method for selecting a cell suspension containing a non-human protein for patient administration. The method involves (a) measuring the amount of at least one non-human protein in a human MSC suspension that was cultured in media containing this protein, and (b) selecting a cell suspension for administration where the amount of non-human protein is less than about 500 μg per kilogram of patient body weight.

• Claim 30: This claims a method for treating or preventing a disease or disorder. It involves (a) providing a pharmaceutical composition of purified MSCs with less than about 55 μg/mL residual BSA, and (b) administering a therapeutically effective amount of this composition to a subject. The key condition is that the administered composition contains less than about 500 μg of BSA per kilogram of patient body weight.

• Claim 31: This claim describes a method for manufacturing a cellular therapy product. The steps include (a) culturing human MSCs in media with non-human serum; (b) harvesting the cells; (c) washing the harvested cells; and (d) recovering purified human MSCs. The recovered composition must contain less than about 55 μg/mL residual BSA.

• Claim 37: This method of manufacturing a cellular therapy product is similar to Claim 31, involving culturing, harvesting, washing, and recovering purified human MSCs. The distinction is that the recovered composition contains MSC aggregates with a D90 of less than about 150 μm.

• Claim 39: This claims a pharmaceutically acceptable cell suspension comprising human MSCs and at least one non-human protein, where the suspension contains less than about 42 μg of the non-human protein per milliliter.

CAFC 2026 Dockets:
A search of CAFC 2026 dockets for US patent 8637004 did not yield any specific results within the 2026 timeframe. The Google Patents page indicates "Family has litigation" and points to a Darts-ip link, suggesting past or ongoing litigation, but no specific CAFC 2026 docket information was readily available through direct search.

I am unable to provide a comprehensive list of known litigation involving US patent 8637004, including plaintiffs, defendants, jurisdiction, case number, filing date, and outcome/current status. This information is typically held within specialized legal databases such as Darts-ip, PACER, or Unified Patents, which require direct access that I do not have.

The Google Patents page for US8637004 indicates "Family has litigation" and provides a link to Darts-ip, suggesting that litigation related to this patent exists and can be found through their service. However, I cannot directly access the Darts-ip database or other similar platforms to retrieve these specific case details.

Proceedings overview

There are no AIA trial proceedings on file for US patent 8637004.

Strategic summary

The absence of any PTAB proceedings (Inter Partes Review, Post-Grant Review, or Covered Business Method reviews) indicates that the claims of US patent 8637004 remain untested by these administrative trial mechanisms. All claims of the patent are currently sustained in their original form. This means there is no estoppel landscape to consider under § 315(e)(2) for any potential petitioner, as no grounds were raised or could have been raised in a prior AIA trial.

Recommended next steps

Given that there are no PTAB proceedings on file for US patent 8637004, a potential defendant facing assertion of this patent would not have the benefit of any invalidated claims or prior art challenges adjudicated at the PTAB. The absence of PTAB activity suggests that the patent's validity has not been challenged through these specific administrative avenues. If a defendant is considering challenging the patent's validity, initiating an IPR (if eligible) would be an available option to explore.

Inventors

The named inventors for US patent 8637004 are: Alla Danilkovich, Robert E. Newman, JR., Samson Tom, Christopher Ton, Zhanling Wang, and Randell G. Young. At the time of the patent application filing (August 14, 2009), these inventors assigned their interest in the patent to OSIRIS THERAPEUTICS, INC., suggesting they were employed by or had a contractual obligation to Osiris Therapeutics, Inc.

Original assignee

The Google Patents record lists Mesoblast International SARL as the "Original Assignee" and the entity by which the application was filed. However, the initial assignments from the inventors were to Osiris Therapeutics, Inc., which later assigned the patent to Mesoblast International SARL. For the purpose of the issued patent (January 28, 2014), Mesoblast International SARL was the assignee.

Osiris Therapeutics, Inc. was an operating company primarily in the regenerative medicine business, developing and marketing cellular therapies, including mesenchymal stem cell products. They shipped products embodying MSCs, such as PROCHYMAL. Osiris was acquired by BioTissue in 2019.

Mesoblast International SARL is a subsidiary of Mesoblast Limited, an Australian publicly traded (ASX:MSB, NASDAQ:MESO) regenerative medicine company. Mesoblast Limited is an operating company focused on developing and commercializing allogeneic mesenchymal lineage stem cell (MLC) therapeutics. Their product candidates, such as Ryoncil™ (remestemcel-L), embody the claims of the patent, and they are actively involved in clinical trials and commercialization efforts. Mesoblast Limited is currently operating.

Assignment timeline

• 2009-09-17 (executed) / recorded 2009-09-25 — Reel 031383/0501

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: YOUNG, RANDELL G., DANILKOVICH, ALLA, NEWMAN, ROBERT E., JR., TOM, SAMSON, TON, CHRISTOPHER, WANG, ZHANLING
  • Assignee: OSIRIS THERAPEUTICS, INC.
  • Correspondent: BRENT D. SHEAR, ESQ., OSIRIS THERAPEUTICS, INC., 701 SWANN AVENUE, BALTIMORE, MD 21225. This correspondent also appears on Reel 031405/0074.
  • Context: Transfer of inventor rights to the employing company.

• 2009-09-17 (executed) / recorded 2009-10-07 — Reel 031405/0074

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: TON, CHRISTOPHER
  • Assignee: OSIRIS THERAPEUTICS, INC.
  • Correspondent: BRENT D. SHEAR, ESQ., OSIRIS THERAPEUTICS, INC., 701 SWANN AVENUE, BALTIMORE, MD 21225. This correspondent also appears on Reel 031383/0501.
  • Context: Transfer of inventor rights to the employing company (likely a separate record for one inventor).

• 2013-10-24 (executed) / recorded 2013-11-01 — Reel 031535/0593

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: OSIRIS THERAPEUTICS, INC.
  • Assignee: MESOBLAST INTERNATIONAL SÀRL
  • Correspondent: KENNETH S. WEITZMAN, WEITZMAN LAW OFFICES LLC, 44 W. CROSS STREET, BALTIMORE, MD 21230.
  • Context: Transfer of patent ownership from one operating company to another.

• 2018-03-28 (executed) / recorded 2018-03-28 — Reel 045759/0917

  • Conveyance: SECURITY AGREEMENT
  • Assignor: MESOBLAST INTERNATIONAL SÀRL
  • Assignee: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
  • Correspondent: ARNOLD & PORTER KAYE SCHOLER LLP, 250 WEST 55TH STREET, NEW YORK, NEW YORK 10019.
  • Context: Patent used as collateral for a financing agreement.

• 2018-07-10 (executed) / recorded 2018-07-10 — Reel 046648/0126

  • Conveyance: SECURITY AGREEMENT
  • Assignor: MESOBLAST INTERNATIONAL SÀRL
  • Assignee: NQP SPV II, L.P., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
  • Correspondent: HERRICK, FEINSTEIN LLP, 2 PARK AVENUE, NEW YORK, NY 10016.
  • Context: Patent used as collateral for another financing agreement.

• 2021-12-09 (executed) / recorded 2021-12-10 — Reel 052495/0369

  • Conveyance: SECURITY INTEREST
  • Assignor: MESOBLAST INTERNATIONAL SÀRL, MESOBLAST LIMITED ACN 109 431 870, MESOBLAST UK LIMITED, MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.)
  • Assignee: OAKTREE FUND ADMINISTRATION, LLC
  • Correspondent: PROSKAUER ROSE LLP, 11 ORANGE AVENUE, SUITE 800, ORLANDO, FL 32801. This correspondent also appears on Reel 055811/0893 and 056150/0675.
  • Context: Patent used as collateral for a financing agreement involving multiple Mesoblast entities.

• 2025-07-30 (executed) / recorded 2025-07-30 — Reel 055811/0893

  • Conveyance: RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT
  • Assignor: HERCULES CAPITAL, INC., AS AGENT
  • Assignee: MESOBLAST INTERNATIONAL SARL
  • Correspondent: PROSKAUER ROSE LLP, 11 ORANGE AVENUE, SUITE 800, ORLANDO, FL 32801. This correspondent also appears on Reel 052495/0369 and 056150/0675.
  • Context: Release of prior security interest, restoring full rights to Mesoblast.

• 2025-12-23 (executed) / recorded 2026-01-02 — Reel 056150/0675

  • Conveyance: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY
  • Assignor: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
  • Assignee: MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.), MESOBLAST LIMITED, MESOBLAST UK LIMITED, MESOBLAST INTERNATIONAL SÀRL
  • Correspondent: PROSKAUER ROSE LLP, 11 ORANGE AVENUE, SUITE 800, ORLANDO, FL 32801. This correspondent also appears on Reel 052495/0369 and 055811/0893.
  • Context: Release of prior security interest, restoring full rights to the Mesoblast entities.

Timeline diagram

timeline
    title Ownership of US 8637004
    2009 : Filed by Mesoblast Intl SARL
         : Inventors to Osiris Therapeutics
    2013 : Osiris to Mesoblast Intl SARL
    2014 : Issued
    2018 : Mesoblast to Hercules Capital SA
         : Mesoblast to NQP SPV II SA
    2021 : Mesoblast to Oaktree Fund SA
    2025 : Hercules Capital releases Mesoblast
    2026 : Oaktree Fund releases Mesoblast

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. All entities in the direct ownership chain (Osiris Therapeutics, Inc. and Mesoblast International SARL) are operating companies involved in cell therapy development and commercialization. The financing entities (Hercules Capital, NQP SPV II, Oaktree Fund Administration) are financial institutions, not shell entities for patent licensing.
2. Known asserter in the chain — Not present. None of the listed assignors or assignees are recognized as high-frequency patent assertion entities (NPEs) based on public directories. Mesoblast Limited is a biotechnology company.
3. Repeat correspondent across the chain — Present.
   • BRENT D. SHEAR, ESQ., OSIRIS THERAPEUTICS, INC., 701 SWANN AVENUE, BALTIMORE, MD 21225, appears as correspondent on Reel 031383/0501 and Reel 031405/0074. This indicates internal counsel for Osiris handled multiple inventor assignments.
   • PROSKAUER ROSE LLP, 11 ORANGE AVENUE, SUITE 800, ORLANDO, FL 32801, appears as correspondent on Reel 052495/0369, Reel 055811/0893, and Reel 056150/0675. This firm handled multiple security interest recordings and releases for Mesoblast entities. While a repeat, this is consistent with an operating company utilizing a large law firm for its corporate financing legal work.
4. Cascading transfers — Not present. The assignments (excluding the security agreements and releases) are spaced several years apart (2009, 2013), and the security agreements/releases reflect ongoing corporate financing rather than rapid, sequential patent sales to shell entities.
5. Pre-litigation transfer — Unclear. The Google Patents page indicates "Family has litigation," but no specific litigation dates for US patent 8637004 are provided to compare against the assignment dates.
6. Bankruptcy fire-sale — Not present. Osiris Therapeutics, Inc. was acquired by BioTissue, not dissolved or sold in bankruptcy. Mesoblast International SARL and its parent Mesoblast Limited are currently operating.
7. Privateering — Unclear. There is no publicly available information within the patent or assignment records to suggest that Mesoblast or Osiris transferred the patent to an NPE to assert on their behalf.
8. Defensive aggregator (anti-NPE) — Not present. The patent is currently held by Mesoblast International SARL, an operating company, and is not listed as being acquired by any known defensive aggregators.

Verdict

Operating-company assertion
This verdict is reached with high confidence. The patent ownership history clearly shows transfers between two operating companies, Osiris Therapeutics, Inc. (2009-2013) and Mesoblast International SARL (2013-present), both of which are actively involved in the development and commercialization of mesenchymal stem cell therapies. The other recorded transactions are security agreements and their subsequent releases, which are standard financing activities for operating companies, not indicative of NPE behavior. There are no signs of shell entities, known patent trolls, or rapid, opaque transfers.

USPTO Assignment Center search for US8637004: https://assignmentcenter.uspto.gov/#!/patent/8637004

To identify the most relevant prior art for US patent 8637004, I will examine the "References Cited" section of the patent as available on Google Patents. The USPTO's Patent Public Search tool can be used to access issued patents and their citations.

Based on the information available on the Google Patents page for US8637004, the "Prior art keywords" section lists: "composition", "mesenchymal stem", "mscs", "paragraph", and "less". While this provides general themes, the specific cited patents and non-patent literature are more critical for a direct prior art analysis.

Here's an analysis of the "References Cited" from US8637004, focusing on those likely to be most relevant for anticipation under 35 U.S.C. § 102:

US Patent References

• US5197985 A
  • Full Citation: US5197985 A, "Human bone marrow stem cells", issued March 30, 1919.
  • Publication/Filing Date: Publication date: March 30, 1993.
  • Brief Description: This patent describes methods for isolating, characterizing, and culturing human mesenchymal stem cells from bone marrow. It also covers methods for inducing differentiation into various mesenchymal tissues.
  • Potential Anticipation: This patent establishes the foundational knowledge of isolating and culturing MSCs. Claims 1, 10, 11, 19, 23, 31, and 37, which generally relate to MSC compositions and methods of preparing them, could potentially be anticipated in terms of the basic concept of MSCs and their culture, but not necessarily the specific purification parameters or aggregate characteristics. However, the purification methods and specific quantitative limits on BSA and aggregate size claimed in US8637004 are likely distinguishing features.
• US5226914 A
  • Full Citation: US5226914 A, "Human mesenchymal stem cell populations", issued July 13, 1993.
  • Publication/Filing Date: Publication date: July 13, 1993.
  • Brief Description: This patent details purified human mesenchymal stem cell populations, their isolation, and methods for proliferation and differentiation.
  • Potential Anticipation: Similar to US5197985, this patent provides foundational teaching on MSC isolation and propagation. Claims 1, 10, 11, 19, 23, 31, and 37 might be anticipated in their broadest sense of MSC compositions. However, the specific purification levels of xenogeneic substances, aggregate size limits, and viability metrics in US8637004 differentiate it.
• US5486359 A
  • Full Citation: US5486359 A, "Methods for isolating, purifying, and expanding human mesenchymal stem cells", issued January 23, 1996.
  • Publication/Filing Date: Publication date: January 23, 1996.
  • Brief Description: This patent focuses on improved methods for isolating, purifying, and expanding human mesenchymal stem cells.
  • Potential Anticipation: This reference, like the others by similar inventors and assignees, further refines MSC handling. Claims 11, 19, 23, 31, and 37, which describe methods of preparing MSC compositions, might find some anticipation in the general steps of isolation and purification. However, the specific centrifugal filtration technique and the resulting quantitative purity and aggregate size limitations in US8637004 are key distinctions.
• US5837539 A
  • Full Citation: US5837539 A, "Human mesenchymal stem cell populations and methods for their use", issued November 17, 1998.
  • Publication/Filing Date: Publication date: November 17, 1998.
  • Brief Description: This patent covers human mesenchymal stem cell populations and methods for their therapeutic use.
  • Potential Anticipation: This patent broadly discusses MSC populations and their therapeutic applications. Claims 1, 10, 29, 30, and 39, which relate to the compositions themselves and their use in treating diseases, might be anticipated in terms of the general therapeutic application of MSCs. However, the specific purification parameters and reduced aggregation properties of the MSCs as defined in US8637004 would likely differentiate it.
• US6087113 A
  • Full Citation: US6087113 A, "Methods for isolating, purifying, and expanding human mesenchymal stem cells", issued July 11, 2000.
  • Publication/Filing Date: Publication date: July 11, 2000.
  • Brief Description: This patent provides methods for isolating, purifying, and expanding human mesenchymal stem cells.
  • Potential Anticipation: Similar to US5486359, this patent focuses on improved methods for MSC handling. Claims 11, 19, 23, 31, and 37 could be anticipated in their general scope of MSC preparation methods. However, the particular centrifugal filtration technique and the resulting specific purity and aggregate size thresholds claimed in US8637004 represent key distinguishing features.
• US6251295 B1
  • Full Citation: US6251295 B1, "Centrifugal filtering apparatus and method", issued June 26, 2001.
  • Publication/Filing Date: Publication date: June 26, 2001.
  • Brief Description: This patent describes a centrifugal filtering apparatus and method, particularly for removing platelets and antibodies from blood products.
  • Potential Anticipation: This patent describes a device and method for centrifugal filtration, which is a core purification technique used in US8637004. Claims 11, 19, 23, 31, and 37, which specifically mention centrifugal filtration, might be anticipated in terms of the device or the general process of centrifugal filtration. However, US8637004 applies this technology to MSC purification to achieve specific residual BSA levels and aggregate size reductions, which are not explicitly taught by US6251295.
• US20080175825 A1
  • Full Citation: US20080175825 A1, "Methods to wash cultured bone marrow mononuclear cells", published July 24, 2008.
  • Publication/Filing Date: Publication date: July 24, 2008.
  • Brief Description: This application details methods for washing cultured bone marrow mononuclear cells, reporting post-wash residual BSA levels and cell viability.
  • Potential Anticipation: This reference is highly relevant as it addresses washing cultured cells and discusses residual BSA levels and viability, similar to the problems US8637004 aims to solve. The patent itself explicitly discusses Hampson et al. (US 2008/0175825) and states that "Post-wash residual BSA levels from the cell culture supernatant were reported to be about less than 3 μg/ml. Using a Cytomate instrument to wash bone marrow mononuclear cells, Hampson et al. obtained about 70% cell viability post-wash. Hampson et al. indicated that this significant drop in cell viability may have been due to cellular damage caused by mechanical forces applied during the process." US8637004 then distinguishes itself by providing compositions with higher viability and superior aggregate profiles, achieved through centrifugal filtration, thus potentially overcoming the limitations mentioned in Hampson et al. While it describes washing and reducing BSA, the specific thresholds for BSA, D90 of aggregates, and high viability achieved simultaneously in US8637004's claims (e.g., Claim 1, 10) likely represent improvements over this prior art.

Non-Patent Literature References

• Cotten HR et al., N Engl J Med, 1975, 292:1050
  • Full Citation: Cotten HR et al., "Bovine serum albumin as a cause of allergic reactions to insulin", N Engl J Med, 1975, 292:1050.
  • Publication Date: 1975.
  • Brief Description: This paper highlights bovine serum albumin (BSA) as a cause of allergic reactions.
  • Potential Anticipation: This reference establishes the problem of BSA-induced allergic reactions, which is a motivation for the purification efforts in US8637004. It does not, however, teach any solutions or specific purification parameters for MSC compositions. Therefore, it does not directly anticipate any claims, but rather sets the problem context.
• Moneret-Vautrin A. et al., Allergy, 1991, 46:228
  • Full Citation: Moneret-Vautrin A. et al., "Allergy to bovine serum albumin: a report of 10 cases", Allergy, 1991, 46:228.
  • Publication Date: 1991.
  • Brief Description: This publication further details cases of allergy to BSA.
  • Potential Anticipation: Similar to Cotten et al., this reference highlights the immunogenicity concern with BSA, providing background for the problem addressed by US8637004. It does not anticipate the claimed solutions.
• Orta M et al., Ann Allergy Asthma Immunol 2003, 90:446
  • Full Citation: Orta M et al., "Anaphylaxis to bovine serum albumin in a patient with Crohn's disease", Ann Allergy Asthma Immunol 2003, 90:446.
  • Publication Date: 2003.
  • Brief Description: This article describes a case of anaphylaxis due to BSA.
  • Potential Anticipation: This NPL emphasizes the severe allergic reactions that can be caused by BSA, reinforcing the need for purification as addressed by US8637004. It does not anticipate any specific claims.
• de Benito V. et al., Allergologia et Immunopathologia, 2001, 29:272
  • Full Citation: de Benito V. et al., "Allergic reactions to bovine serum albumin in patients with food allergy", Allergologia et Immunopathologia, 2001, 29:272.
  • Publication Date: 2001.
  • Brief Description: This publication discusses allergic reactions to BSA in the context of food allergy.
  • Potential Anticipation: This reference contributes to the understanding of BSA's allergenic potential, which informs the problem statement of US8637004. No direct anticipation of claims.
• Spees et al., Mol Therapy, 2004, 9: 747
  • Full Citation: Spees et al., "Differences in serum-free versus serum-containing culture conditions on the differentiation potential of human mesenchymal stem cells", Mol Therapy, 2004, 9: 747.
  • Publication Date: 2004.
  • Brief Description: This article discusses culture conditions for MSCs, including the use of fetal calf serum (FCS) and autologous human serum, and mentions residual FCS. The patent itself states: "Residual BSA resulting from published methods is generally reported to be about 30-700 μg BSA per 1×10^6 cells (Spees et al., Mol Therapy, 2004, 9: 747)".
  • Potential Anticipation: This NPL provides context for residual xenogeneic substances in MSC cultures and their variability. While it reports residual FCS (and by extension BSA) levels, it doesn't disclose the specific purification methods (centrifugal filtration) or the resulting reduced levels and aggregate characteristics claimed in US8637004. It serves as evidence of the state of the art prior to the invention. The patent explicitly states that the present technology achieves "greater than 200-fold reduction in BSA between the published compositions and methods relative to the present technology", implying that Spees et al. would not anticipate the claimed BSA levels.
• Moneret-Vautrin A. & Kanny G., Curr Opin Allergy Clin Immunol, 2004, 4:215
  • Full Citation: Moneret-Vautrin A. & Kanny G., "Threshold doses for food allergens", Curr Opin Allergy Clin Immunol, 2004, 4:215.
  • Publication Date: 2004.
  • Brief Description: This paper discusses threshold doses for food allergens and notes that thresholds for IV exposure remain unknown.
  • Potential Anticipation: This reference establishes the critical problem that US8637004 seeks to solve regarding IV administration safety thresholds, but does not provide solutions. Claim 29 (method of selecting a cell suspension based on non-human protein amount per kg patient body weight) and Claim 30 (method of treating using a composition with less than 500 μg BSA per kg patient body weight) directly address the "unknown thresholds for IV exposure" problem identified in this NPL. Thus, while it doesn't anticipate the solution, it clearly defines a problem that US8637004 claims to have solved.
• Bindslev-Jensen C et al., Allergy, 2002, 57:741
  • Full Citation: Bindslev-Jensen C et al., "Cutaneous responses to histamine in allergic and non-allergic individuals", Allergy, 2002, 57:741.
  • Publication Date: 2002.
  • Brief Description: This NPL relates to allergic reactions but is less directly cited for BSA or MSC context than others.
  • Potential Anticipation: Provides general background on allergy, but not directly anticipatory of the claims.
• Wensing M. et al., J Allergy Clin Immunol, 2002, 110:915
  • Full Citation: Wensing M. et al., "Prevalence of IgE to bovine serum albumin (BSA) in children with cow's milk allergy", J Allergy Clin Immunol, 2002, 110:915.
  • Publication Date: 2002.
  • Brief Description: Discusses IgE responses to BSA in cow's milk allergy, further reinforcing the immunogenicity of BSA.
  • Potential Anticipation: Similar to other NPL regarding BSA immunogenicity, it sets the problem context for US8637004 but does not anticipate the claimed solutions.
• Taylor SL et al., Clin Exp Allergy, 2004, 34:689
  • Full Citation: Taylor SL et al., "Food allergen thresholds: why they are important and how they are established", Clin Exp Allergy, 2004, 34:689.
  • Publication Date: 2004.
  • Brief Description: Discusses food allergen thresholds and reiterates that IV exposure thresholds are unknown.
  • Potential Anticipation: This NPL reinforces the problem addressed by US8637004, specifically regarding the lack of IV exposure thresholds, making it highly relevant to the problem-solution context of claims like 29 and 30.
• Perotti CG et al., Transfusion, 2004, 44(6):900-906
  • Full Citation: Perotti CG et al., "Centrifugal filtration for removal of cryopreservative DMSO from umbilical cord blood", Transfusion, 2004, 44(6):900-906.
  • Publication Date: 2004.
  • Brief Description: Mentions centrifugal filtration for removing DMSO from umbilical cord blood.
  • Potential Anticipation: This reference suggests the use of centrifugal filtration for removing cryopreservatives, which is a technique used in US8637004. While it applies centrifugal filtration, it's for a different cell type (umbilical cord blood) and a different primary contaminant (DMSO) than the core problem of residual xenogeneic proteins and aggregate reduction in MSCs targeted by US8637004. Therefore, it might anticipate the general technique of centrifugal filtration but not its specific application to MSCs to achieve the claimed purity and aggregate reduction.
• Calmels B et al., Bone Marrow Transplant., 2003, 31(9):823-828
  • Full Citation: Calmels B et al., "Optimization of DMSO removal from hematopoietic stem cell grafts by centrifugal filtration", Bone Marrow Transplant., 2003, 31(9):823-828.
  • Publication Date: 2003.
  • Brief Description: Discusses centrifugal filtration for removing DMSO from hematopoietic stem cell grafts.
  • Potential Anticipation: Similar to Perotti et al., this NPL describes centrifugal filtration for removing DMSO, but from hematopoietic stem cells. The general technique might be anticipated, but its specific application to MSCs to achieve the claimed BSA and aggregate parameters in US8637004 would likely be considered novel.
• Hilton J. et al., Food Chem Toxicol, 1997, 35:1209
  • Full Citation: Hilton J. et al., "Allergenicity of bovine serum albumin and bovine gamma globulin", Food Chem Toxicol, 1997, 35:1209.
  • Publication Date: 1997.
  • Brief Description: This paper compares the allergenicity of BSA to other proteins like ovalbumin (OVA), stating BSA has significantly lower allergenic potential than OVA.
  • Potential Anticipation: This NPL provides context for the choice of ovalbumin as a model in the patent's experimental section (Example 1) due to its higher immunogenicity, confirming that BSA is an allergen. It does not anticipate any claimed solutions.

Most Relevant Prior Art for Anticipation (35 U.S.C. § 102)

The most relevant prior art for potential anticipation of US8637004 under 35 U.S.C. § 102 are likely:

1. US20080175825 A1 (Hampson et al.): This patent application directly addresses methods for washing cultured bone marrow mononuclear cells and discusses residual BSA levels and cell viability. The claims in US8637004 regarding specific residual BSA concentrations and post-purification viability directly build upon or differentiate from the teachings of Hampson et al. The patent itself highlights how its invention improves upon the viability issues noted in Hampson et al.
2. US6251295 B1 (Centrifugal filtering apparatus): While not specific to MSCs, this patent describes the core technology (centrifugal filtration) utilized in US8637004's purification methods. If any claims in US8637004 are broadly drawn to merely using centrifugal filtration for cell washing without the specific parameters related to MSCs, BSA levels, or aggregation, then this reference could be highly anticipatory. However, US8637004 applies this known technology to solve specific problems related to MSCs.
3. Spees et al., Mol Therapy, 2004: This non-patent literature provides context for residual FCS/BSA levels in MSC cultures, setting a baseline against which the improved purity of US8637004's compositions can be measured. The patent explicitly positions its invention as a significant improvement over the BSA levels reported by Spees et al.
4. Moneret-Vautrin A. & Kanny G., Curr Opin Allergy Clin Immunol, 2004, and Taylor SL et al., Clin Exp Allergy, 2004: These NPLs are highly relevant as they explicitly state the "unknown thresholds for IV exposure to allergens," which is a problem directly solved by claims 29 and 30 of US8637004 by establishing such thresholds. While not anticipating the solution itself, they clearly lay out the problem that the invention purports to solve.

The other cited patents by Osiris/Mesoblast inventors (US5197985, US5226914, US5486359, US5837539, US6087113) establish the general field of MSC isolation, culture, and therapeutic use. They would be foundational for obviousness arguments but less likely to anticipate the specific purification parameters and aggregate characteristics claimed in US8637004, which are the novel aspects of this patent. Similarly, the NPL discussing BSA allergenicity (Cotten et al., Moneret-Vautrin et al., Orta et al., de Benito V. et al., Wensing M. et al., Hilton J. et al.) and DMSO removal by centrifugal filtration (Perotti et al., Calmels et al.) provide background and motivation but do not directly disclose the specific combination of features claimed in US8637004.

Obviousness Analysis (35 U.S.C. § 103) for US8637004

This analysis considers whether the claims of US patent 8637004 would have been obvious to a person having ordinary skill in the art (PHOSITA) at the time of the invention (priority date August 14, 2008), based on the identified prior art. A PHOSITA in this field would likely possess a strong background in cell biology, regenerative medicine, biopharmaceutical manufacturing, and immunology. They would be aware of standard cell culture techniques, various cell separation methods, and the regulatory and safety considerations for therapeutic products, particularly those administered intravenously.

The patent itself identifies two key challenges: (1) reducing the immunogenicity of MSC compositions cultured in non-human serum (a previously recognized long-felt need); and (2) reducing the extent of MSC aggregation (a challenge the patent claims to have "surprisingly identified" and "not been previously recognized in the conventional art as a significant shortcoming"). These points will be critical in assessing obviousness.

Combination 1: Centrifugal Filtration for Reduced Xenogeneic Substances

• Prior Art:

  • US20080175825 A1 (Hampson et al.): Discloses methods for washing cultured bone marrow mononuclear cells, aiming to reduce residual BSA, and reports post-wash viability of about 70%. However, it notes that a significant drop in cell viability "may have been due to cellular damage caused by mechanical forces applied during the process."
  • Spees et al., Mol Therapy, 2004: Reports residual fetal calf serum (FCS) per sample and highlights a wide range in residual FCS, indicating a general problem with xenogeneic protein contamination in MSC cultures (30-700 μg BSA per 1×10^6 cells).
  • US6251295 B1: Describes a centrifugal filtering apparatus and method, generally useful for removing platelets and antibodies from blood products.
  • Perotti et al., Transfusion, 2004 & Calmels et al., Bone Marrow Transplant., 2003: Both describe the use of centrifugal filtration for removing cryopreservative DMSO from umbilical cord blood and hematopoietic stem cell grafts, respectively.
  • Cotten HR et al., N Engl J Med, 1975; Moneret-Vautrin A. et al., Allergy, 1991; Orta M et al., Ann Allergy Asthma Immunol 2003; de Benito V. et al., Allergologia et Immunopathologia, 2001; Wensing M. et al., J Allergy Clin Immunol, 2002; Hilton J. et al., Food Chem Toxicol, 1997: These non-patent literature (NPL) references establish the widespread awareness of BSA's immunogenicity and allergenic potential, motivating its reduction in therapeutic products.

• Motivation for Combination: A PHOSITA would be highly motivated to reduce xenogeneic substances like BSA from MSC compositions due to their known immunogenicity and potential for adverse reactions. Hampson et al. attempted to address this with washing, but noted concerns about cell viability. Given that centrifugal filtration was a known technique for separating cells from undesired components in biological fluids (US6251295) and for removing contaminants like DMSO from other types of stem cells (Perotti et al., Calmels et al.), a PHOSITA would have been motivated to try centrifugal filtration as an improved method for purifying MSCs. This would be a logical step to address the known problem of high residual xenogeneic proteins (Spees et al.) and potentially mitigate the cell damage observed with other washing methods (Hampson et al.).

• Obviousness Assessment for Claims 1, 11, 31, 39 (BSA reduction):

  • Claim 1: "A pharmaceutically acceptable composition comprising purified mesenchymal stem cells, wherein the composition comprises less than about 55 μg/mL residual bovine serum albumin and wherein the mesenchymal stem cells exhibit a D90 between about 18 μm and about 30 μm."
  • Claim 11: Method using centrifugal filtration to achieve less than about 55 μg/mL residual non-human serum protein.
  • Claim 31: Manufacturing method to achieve less than about 55 μg/mL residual BSA.
  • Claim 39: Cell suspension with less than about 42 μg/mL non-human protein.

  While the motivation to reduce BSA is clear, the specific quantitative thresholds for residual BSA (e.g., less than 55 μg/mL or less than 42 μg/mL) and the "greater than 200-fold reduction in BSA between the published compositions and methods relative to the present technology" could be argued as an unexpected result, particularly if achieved while maintaining high cell viability (which Hampson et al. struggled with). The PHOSITA might have been motivated to try centrifugal filtration, but achieving these specific, significantly reduced levels, especially without compromising cell viability or therapeutic function, might not have been predictable without undue experimentation. If the method of centrifugal filtration (as combined from prior art) was found to achieve these specific low BSA levels without specific further inventive steps for that outcome, then these claims could be considered obvious. However, the patent explicitly states that the reduction was "significant and surprisingly unexpected".

Combination 2: Addressing MSC Aggregation

• Prior Art: The patent explicitly states, "the present technology described and claimed herein surprisingly identified a challenge that had not been previously recognized in the conventional art as a significant shortcoming: reducing the extent of MSC aggregation." It further states, "The present technology first recognized that the formation of an aggregate comprising MSCs can lead to pulmonary emboli." It links increased xenogeneic substances and cell surface molecules to increased cellular adhesion and aggregation.

• Motivation for Combination: If the problem of MSC aggregation and its potential to cause pulmonary emboli was truly unrecognized by a PHOSITA, then there would have been no motivation in the prior art to combine existing purification techniques to specifically reduce aggregate size (D90 less than 150 μm, or MSC D90 18-30 μm) for this purpose. A PHOSITA might have sought to reduce xenogeneic proteins for immunogenicity reasons, but the link between these substances, aggregation, and clinical risk (pulmonary emboli) was, according to the patent, a novel recognition. Without this recognition, there would be no motivation to modify existing purification processes to achieve specific aggregate size profiles.

• Obviousness Assessment for Claims 1, 10, 19, 23, 37 (Aggregation):

  • Claim 1: Composition with MSCs exhibiting a D90 between about 18 μm and about 30 μm.
  • Claim 10: Composition with aggregates D90 less than about 150 μm and MSC D90 between about 18 μm and about 30 μm.
  • Claim 19: Method using centrifugal filtration resulting in aggregates D90 less than about 150 μm.
  • Claim 23: Method using centrifugal filtration resulting in MSCs exhibiting a D90 between about 18 μm and about 30 μm.
  • Claim 37: Manufacturing method resulting in aggregates D90 less than about 150 μm.

  These claims, particularly those specifying aggregate D90 values (less than 150 μm) or MSC D90 values (18-30 μm), derive significant non-obviousness strength from the patent's assertion that the aggregation problem was previously unrecognized. If a PHOSITA was not motivated to solve an unrecognized problem, then the claimed solution for that problem would be non-obvious. The patent's findings that centrifugal filtration "reduces the average size of MSC aggregates by decreasing the adhesive properties of individual MSCs" and that it "simultaneously (i) reduces the immunogenicity of MSC compositions; and, (ii) reduces the average size of MSC aggregates" could be considered unexpected results of applying centrifugal filtration, beyond merely reducing BSA.

Combination 3: Establishment of IV Exposure Thresholds

• Prior Art:

  • Moneret-Vautrin A. & Kanny G., Curr Opin Allergy Clin Immunol, 2004 & Taylor SL et al., Clin Exp Allergy, 2004: Both explicitly state that while risk doses and thresholds for oral administration of antigens are established, "thresholds for IV exposure to allergens remain unknown." This highlights a significant unmet need.
  • Hilton J. et al., Food Chem Toxicol, 1997: Provides context on comparing allergenicity, noting Ovalbumin (OVA) is more immunogenic than BSA.
  • General knowledge of toxicology/experimental design: A PHOSITA would be familiar with animal models and experimental designs for determining safety thresholds for pharmaceutical products.

• Motivation for Combination: The explicit statement in multiple NPL references that IV exposure thresholds for allergens were unknown would create a strong motivation for a PHOSITA developing IV cell therapies to determine such thresholds for patient safety and regulatory compliance. Using an animal model and a representative xenogeneic protein like OVA (as described in Example 1 of US8637004, and supported by Hilton et al. as an appropriate, more immunogenic surrogate for BSA) would be a logical and well-known approach in pharmaceutical toxicology.

• Obviousness Assessment for Claims 29 and 30 (IV Thresholds):

  • Claim 29: Method of selecting a cell suspension based on less than about 500 μg non-human protein per kilogram of patient body weight.
  • Claim 30: Method of treating with an MSC composition, where less than about 500 μg BSA per kilogram of patient body weight is administered.

  While the motivation to determine IV thresholds was clearly present in the prior art, the specific numerical value of less than 500 μg/kg of non-human protein is an empirical discovery derived from the experiments detailed in the patent (Example 1). A PHOSITA, motivated by the known problem, would have tried to establish such a threshold. The process of using an animal model and an allergen surrogate to find a No Observed Adverse Effect Level (NOAEL) or similar safety limit for IV administration could be considered an obvious experimental design. However, the discovery of the specific threshold itself, and its application to MSC therapies, could be considered non-obvious if the results were unexpected or if the experimental design leading to that specific threshold required inventive steps beyond routine experimentation. The patent describes the determination of "the lowest cumulative OVA dose that does not trigger sensitization when delivered IP is 10 μg/mouse, corresponding to 500 μg/kg based on average 20 g mouse body weight", and then applying this as a safe cumulative dose for animal protein residuals in MSC pharmaceutical compositions. This quantitative link and subsequent application might represent a non-obvious advance.

Conclusion on Obviousness

The strongest arguments for non-obviousness for US8637004 lie in the patent's claim of having identified a previously unrecognized problem regarding MSC aggregation and its link to pulmonary emboli, and the provision of compositions and methods that address this. If this problem was truly unknown, then the claims related to achieving specific aggregate D90 values or MSC D90 values (Claims 1, 10, 19, 23, 37) would be non-obvious, as there would be no motivation in the prior art to pursue such specific outcomes.

For the reduction of xenogeneic substances (BSA) (Claims 1, 11, 31, 39), the general motivation to reduce such contaminants was present. The application of centrifugal filtration to MSCs for this purpose, given its known utility in cell separation and contaminant removal from other cell types, could be argued as obvious to try. However, the degree of reduction achieved (e.g., "greater than 200-fold reduction") and the associated improvements in safety margins, especially when coupled with maintained high cell viability, could support non-obviousness as an unexpected result.

For the establishment of IV exposure thresholds (Claims 29, 30), the motivation to determine such thresholds was clearly present in the prior art (explicitly stated as "unknown"). The methodology for determining safety thresholds using animal models and allergen surrogates is generally known in the pharmaceutical field. Therefore, the method of determining the threshold might be obvious. However, the discovery of the specific numerical threshold of 500 μg/kg and its direct application to human MSC products to provide a quantifiable safety standard for IV administration could be a non-obvious empirical discovery, particularly in the context of a new class of therapeutics (MSCs).

In summary, while some components of the invention (e.g., using centrifugal filtration for cell washing) might be considered obvious to try in combination with existing knowledge, the specific quantitative achievements in BSA reduction, the resolution of the unrecognized MSC aggregation problem, and the establishment of concrete IV safety thresholds collectively present stronger arguments for non-obviousness.

To provide a comprehensive overview of US patent 8637004's term and family information, I will consult the USPTO Patent Center and Google Patents.

Here's a breakdown of the requested information for US Patent 8637004:

Patent Term Adjustments (PTA)

Patent Term Adjustments (PTA) are granted to compensate for delays incurred during the patent examination process at the United States Patent and Trademark Office (USPTO). The Google Patents page for US8637004 indicates an "Adjusted expiration" date of 2032-02-18. Given the statutory patent term of 20 years from the earliest priority filing date (August 14, 2008), which would typically lead to an expiration date of August 14, 2028, the adjusted expiration date indicates that Patent Term Adjustment (PTA) has been applied. This adjustment extends the patent term beyond the initial 20 years.

Patent Term Extensions (PTE)

Patent Term Extensions (PTE) are awarded to compensate for delays in obtaining regulatory approval on a patented product or methods of manufacturing or using the product, especially relevant for pharmaceuticals and medical devices. There is no explicit mention of Patent Term Extension (PTE) being granted for US8637004 on the Google Patents page. While the technology is in a field where PTE could be sought (cellular therapy), the adjusted expiration date noted is typically associated with PTA, not PTE, unless otherwise specified.

Continuation Applications

Continuation applications allow applicants to pursue additional claims based on the same disclosure as the original patent application. US8637004 (Application number US12/541,282, filed 2009-08-14) is part of a patent family. The "Other versions" section on Google Patents lists US20100068191A1, which is the publication of the original application for US8637004.

The patent record also shows priority claims to subsequent applications, which can indicate continuation, divisional, or continuation-in-part applications:

• Priority to US14/107,031 (2013-12-16) -> This corresponds to US20140105872A1. This is a continuation application.
• Priority to US15/602,848 (2017-05-23) -> This corresponds to US20180008642A1. This is a continuation application.
• Priority to US16/694,382 (2019-11-25) -> This corresponds to US20200197444A1. This is a continuation application.
• Priority to US17/934,852 (2022-09-23) -> This corresponds to US20230089901A1. This is a continuation application.
• Priority to US19/086,003 (2025-03-20) -> This corresponds to US20250312379A1. This is a continuation application.

These subsequent applications indicate a strategy of filing continuation applications to broaden or refine claims based on the initial disclosure.

Divisional Applications

Divisional applications are filed when an examiner determines there is more than one invention in an original patent application (a "restriction requirement"). They enjoy a "safe harbor" from certain double patenting rejections. The Google Patents page for US8637004 does not explicitly label any of the related applications as "divisional." The listed priority claims are typically indicative of continuation applications. However, without direct access to the USPTO's PAIR system or detailed file histories, it's not possible to definitively rule out a divisional application being filed from one of the parent applications.

Related Family Members

The patent family members, as indicated by the priority claims on Google Patents and other versions, include:

• US8637004B2 (Issued patent)
• US20100068191A1 (Publication of the original application, precursor to US8637004B2)
• US12/541,282 (Original application number for US8637004)
• US14/107,031 (Application number for US20140105872A1, a continuation)
• US20140105872A1 (Publication of a continuation application)
• US15/602,848 (Application number for US20180008642A1, a continuation)
• US20180008642A1 (Publication of a continuation application)
• US16/694,382 (Application number for US20200197444A1, a continuation)
• US20200197444A1 (Publication of a continuation application)
• US17/934,852 (Application number for US20230089901A1, a continuation)
• US20230089901A1 (Publication of a continuation application)
• US19/086,003 (Application number for US20250312379A1, a continuation)
• US20250312379A1 (Publication of a continuation application)

This shows an active prosecution strategy within the patent family, with several continuation applications being filed over time.

Projected Expiration Date

The statutory term of a utility patent in the United States is generally 20 years from the filing date of the earliest non-provisional application from which benefit is claimed. The priority date for US8637004 is August 14, 2008. Without any adjustments or extensions, the patent would expire on August 14, 2028.

However, the Google Patents page explicitly states "Adjusted expiration: 2032-02-18". This adjusted date includes Patent Term Adjustment (PTA) granted due to administrative delays during prosecution.

Therefore, the projected expiration date for US patent 8637004 is February 18, 2032.

Defensive Disclosure Document for US Patent 8637004

This document outlines derivative variations of US Patent 8637004, focusing on core claims related to purified mesenchymal stem cell (MSC) compositions, purification methods, and dosing criteria. The intent is to establish prior art that pre-empts future incremental improvements by rendering them obvious or non-novel, based on the principles of material/component substitution, operational parameter expansion, cross-domain application, integration with emerging technologies, and inverse/failure modes.

---

Core Concept 1: Purified MSC Composition with Specific Characteristics

(Deriving from claims like 1, 10, 39, focusing on low residual BSA, controlled aggregate size (D90), and viable MSCs.)

Derivative 1.1: Material & Component Substitution – Alternative Cryoprotectants and Stabilizing Agents

Enabling Description: A pharmaceutically acceptable composition of purified human mesenchymal stem cells (hMSCs) is prepared where fetal bovine serum (FBS) derived bovine serum albumin (BSA) is reduced to less than 5 μg/mL. Instead of dimethyl sulfoxide (DMSO) as the sole cryoprotectant, the composition employs a binary cryopreservation system comprising 5% (v/v) trehalose and 5% (v/v) polyvinylpyrrolidone (PVP K30) in a buffered electrolyte solution (e.g., PlasmaLyte A or lactated Ringer's solution). This formulation aims to mitigate cellular stress during freezing and thawing, maintaining post-thaw viability greater than 90% and an MSC D90 between 18 μm and 25 μm, with aggregate D90 less than 100 μm. The trehalose provides intracellular cryoprotection, while PVP K30 stabilizes cell membranes and prevents ice crystal formation. The purification to achieve the specified BSA and aggregate parameters is performed via tangential flow filtration using polysulfone hollow fiber membranes with a 0.2 μm pore size.

graph TD
    A[Cultured hMSCs] --> B{Centrifugal Filtration / TFF};
    B -- Reduced BSA, Aggregates --> C[Washed hMSC Concentrate];
    C --> D{Mix with Cryopreservative System};
    D --> E[5% Trehalose, 5% PVP K30, Electrolyte Buffer];
    E --> F[Purified hMSC Composition];
    F --> G(Cryopreservation/Storage);
    G --> H(Administration);

Derivative 1.2: Operational Parameter Expansion – Ultra-High Concentration MSC Compositions

Enabling Description: A highly concentrated pharmaceutical composition of purified hMSCs is manufactured, targeting a cell density exceeding 200 x 10^6 cells/mL. This composition maintains residual bovine serum albumin (BSA) levels below 1 μg/mL and ensures that the mesenchymal stem cells exhibit a D90 between 20 μm and 30 μm. Crucially, the D90 of any cell aggregates present is maintained below 50 μm, even at this high cellular density, through a multi-stage purification process involving sequential centrifugal filtration followed by microfluidic flow-focusing for fine-tuned aggregate size exclusion. The increased viscosity of the concentrated cell suspension necessitates specialized rheological modifiers, such as hyaluronic acid at 0.1% (w/v), to facilitate administration while preventing shear-induced damage and maintaining cell viability above 95% post-purification and cryopreservation.

graph TD
    A[Cultured hMSCs] --> B{Multi-Stage Centrifugal Filtration};
    B -- <1 µg/mL BSA --> C[Primary Purified hMSC Concentrate];
    C --> D{Microfluidic Flow-Focusing};
    D -- Aggregate D90 < 50 µm --> E[Ultra-High Density hMSC Suspension];
    E --> F{Add Hyaluronic Acid / Cryoprotectant};
    F --> G[Final Ultra-Concentrated hMSC Composition];
    G --> H(Storage/Administration);

Derivative 1.3: Cross-Domain Application – Purified Cell-like Particles for Drug Delivery in Oncology

Enabling Description: A composition comprising purified, non-aggregating, biocompatible polymeric nanoparticles (instead of MSCs) for targeted drug delivery in oncology. These nanoparticles, engineered to mimic cell-surface adhesion properties, are purified to achieve a D90 between 50 nm and 100 nm, with aggregate D90 less than 200 nm. The purification process, utilizing a scaled-down centrifugal filtration system with molecular weight cut-off membranes, ensures residual manufacturing impurities (e.g., unreacted monomers, surfactants, or solvent residues) are reduced to below 1 ng/mL. The nanoparticles are loaded with a chemotherapeutic agent and surface-functionalized with antibodies targeting specific cancer biomarkers (e.g., HER2, PD-L1). The reduced aggregation ensures uniform distribution and improved tumor penetration upon systemic administration, minimizing off-target effects and maximizing therapeutic index.

graph TD
    A[Synthesized Nanoparticles + Drug Payload] --> B{Scaled Centrifugal Filtration (MWCO)};
    B -- <1 ng/mL Impurities --> C[Purified Nanoparticle Suspension];
    C --> D{Surface Functionalization (Antibodies)};
    D --> E[Targeted Drug Delivery System];
    E --> F(Oncological Administration);

Derivative 1.4: Integration with Emerging Tech – IoT-Monitored Compositions

Enabling Description: A pharmaceutical composition of purified hMSCs, with residual BSA less than 10 μg/mL and aggregate D90 less than 100 μm, contained within a cryopreservative vehicle. Each vial of the composition is equipped with an integrated, miniaturized Internet of Things (IoT) sensor tag, wirelessly transmitting real-time data on storage temperature, cumulative freeze-thaw cycles, and vibrational stress profiles. This sensor data is securely logged to a blockchain network at critical supply chain junctures, enabling immutable verification of storage conditions from manufacturing to point-of-care. The system proactively alerts clinicians if predefined critical parameters (e.g., temperature excursions, excessive agitation) that could compromise cell viability or aggregation state are detected, thereby ensuring product integrity and patient safety.

sequenceDiagram
    participant M as Manufacturing
    participant S as Smart Vial (IoT Sensor)
    participant C as Cold Chain Logistics
    participant P as Point-of-Care (Clinic)
    participant B as Blockchain Ledger

    M->S: Embed IoT Sensor in Vial
    M->S: Load Purified hMSCs
    S->>B: Initial State (Batch ID, Purity, Aggregation D90)
    S->>C: Transmit Temp/Vibration Data
    C->>B: Log Storage Event + Sensor Data
    C->>P: Deliver Vial
    S->>P: Transmit Real-time Condition
    P->>B: Log Receipt/Preparation
    alt Critical Threshold Exceeded
        S->>P: Alert: Condition Compromised!
    end
    P->>P: Administer to Patient

Derivative 1.5: The "Inverse" or Failure Mode – Biocompatible "Sacrificial" Compositions

Enabling Description: A modified MSC composition designed for a safe "failure mode" where, upon detection of specific adverse physiological conditions (e.g., overwhelming systemic inflammation or localized infection at the administration site), the MSCs undergo a controlled, enhanced apoptosis and rapid degradation, effectively neutralizing their therapeutic immunomodulatory effects and preventing unintended long-term engraftment or immunogenic response. This "sacrificial" composition is purified to maintain residual BSA below 55 μg/mL and aggregate D90 less than 150 μm, but further includes a genetically encoded suicide switch (e.g., inducible caspase activation system) within the MSCs. This ensures that while the initial purification and aggregate control are maintained for safety, the cells are programmed for self-elimination under specific trigger conditions, thereby preventing potential immunogenic complications in a compromised host.

stateDiagram-v2
    state CompositionReady {
        [*] --> PurifiedMSCs
        PurifiedMSCs --> SentinelMode: Administered to patient
    }
    state SentinelMode {
        SentinelMode --> ControlledApoptosis: TriggerDetected (e.g., High Inflammatory Markers)
        ControlledApoptosis --> Degradation: Apoptosis initiated
        Degradation --> Elimination: Neutralized therapeutic effect
        SentinelMode --> TherapeuticAction: No TriggerDetected
    }
    state TherapeuticAction {
        TherapeuticAction --> LongTermEngraftment
    }

    PurifiedMSCs: <55µg/mL BSA, Agg. D90 < 150µm, Suicide Gene
    TriggerDetected: Systemic Inflam., Infection

---

Core Concept 2: Centrifugal Filtration Purification Method

(Deriving from claims like 11, 19, 23, 31, 37, focusing on using centrifugal filtration to achieve low xenogeneic substances and controlled aggregation/MSC size.)

Derivative 2.1: Material & Component Substitution – Ceramic Membrane Centrifugal Filtration

Enabling Description: A method for preparing purified hMSCs utilizing a centrifugal filtration system equipped with robust, sterilizable ceramic membranes composed of alumina-zirconia composites, having a precisely controlled pore size of 0.5 μm to 3 μm. This non-polymeric membrane material offers superior chemical resistance and mechanical stability, enabling aggressive cleaning-in-place (CIP) and steam-in-place (SIP) protocols, thus reducing cross-contamination risks and extending membrane lifespan in large-scale biopharmaceutical manufacturing. The method comprises contacting culture-expanded hMSCs (containing residual FBS) with a biocompatible wash solution (e.g., PlasmaLyte A with 0.1% human serum albumin), agitating the mixture in a turbulent flow regime within the filter housing, and recovering purified hMSCs via tangential flow through the ceramic membrane. This process consistently achieves less than 5 μg/mL residual non-human serum protein and maintains MSC aggregate D90 below 75 μm with cell viability exceeding 90%.

graph TD
    A[Cultured hMSCs + FBS] --> B{Mixing Tank + Wash Solution (HSA)};
    B --> C{Ceramic Centrifugal Filter (0.5-3µm)};
    C -- Permeate (Residual FBS, Debris) --> D[Waste/Recycle];
    C -- Retentate (Washed hMSCs) --> E[Purified hMSC Collection];
    E --> F(Final Formulation);
    F --> G{CIP/SIP Cycles};
    G --> C;

Derivative 2.2: Operational Parameter Expansion – Continuous, High-Throughput Centrifugal Filtration

Enabling Description: A method for industrial-scale preparation of purified hMSCs involving a continuous-flow, multi-stage centrifugal filtration system. This system is designed for a throughput exceeding 100 liters/hour, processing billions of hMSCs, while maintaining residual BSA levels below 10 μg/mL and ensuring that the hMSC aggregate D90 is less than 100 μm. The operational parameters include a feed flow rate of 2 L/min, transmembrane pressure differential of 5-10 psi, and a recirculation rate of 10-15 L/min through a series of spirally wound polymeric membranes with 5 μm nominal pore size. Automated sensor arrays continuously monitor cell density, viability (via fluorescent probes), BSA concentration (via in-line immunoassay), and aggregate size (via dynamic light scattering) in real-time. The system automatically adjusts pump speeds and wash solution input to maintain optimal purification kinetics and product quality, significantly reducing batch processing times and labor costs.

graph LR
    A[MSC Culture Bioreactor] --> F{Feed Pump};
    F --> B(Primary CF Module);
    B -- Filtrate (BSA, Debris) --> C[Waste Stream];
    B -- Retentate --> D(Secondary CF Module);
    D -- Filtrate --> C;
    D -- Retentate --> E[Purified MSC Product Tank];
    E --> H(Quality Control & Formulation);

    subgraph Real-time Monitoring & Control
        Sensor1(Cell Density)
        Sensor2(Viability)
        Sensor3(BSA Immunoassay)
        Sensor4(DLS for Aggregation)
        Sensor1, Sensor2, Sensor3, Sensor4 -- Data --> ControlUnit(Automated Process Control)
        ControlUnit --> F, B, D;
    end

Derivative 2.3: Cross-Domain Application – Micro-scale Centrifugal Filtration for Pathogen Removal in Water Purification

Enabling Description: A method for purifying potable water from a contaminated source by employing a micro-scale centrifugal filtration device, originally adapted from MSC purification technology, to remove pathogenic microorganisms (e.g., bacteria, protozoa, viral aggregates) while retaining essential minerals. The device incorporates a series of rapidly spinning hollow fiber membranes (pore size 0.05 μm to 0.2 μm) within a compact cartridge, processing water at a flow rate of 1-5 mL/minute. The centrifugal force enhances filtration efficiency, preventing membrane fouling by continuously sweeping the membrane surface. The method ensures that residual pathogen load is reduced by at least 5 log units, significantly below drinking water standards, with minimal impact on water chemistry. This process is particularly suitable for portable or point-of-use water purification systems in remote or disaster-stricken areas.

graph TD
    A[Contaminated Water Source] --> B{Pre-filter (Sediment)};
    B --> C{Micro-Centrifugal Filter Cartridge};
    C -- Retentate (Pathogens, Particulates) --> D[Waste Collection];
    C -- Permeate (Purified Water) --> E[Potable Water Outlet];
    E --> F(Mineral Re-balancing, Optional);

Derivative 2.4: Integration with Emerging Tech – AI-Optimized Centrifugal Filtration

Enabling Description: A method for purifying hMSCs where the centrifugal filtration process parameters (e.g., flow rate, transmembrane pressure, centrifugation speed, wash buffer volume, number of wash cycles) are continuously monitored and dynamically optimized by an artificial intelligence (AI) engine. Optical sensors (e.g., particle counters, turbidity meters) and biochemical assays (e.g., in-line BSA detection, viability staining) provide real-time feedback to the AI. The AI, trained on extensive datasets of purification runs, predicts optimal parameter adjustments to achieve target residual BSA levels (e.g., < 5 μg/mL), minimize cell aggregation (aggregate D90 < 75 μm), and maximize post-purification viability (> 95%) simultaneously, accounting for batch-to-batch variations in initial cell quality and culture conditions. This predictive control system significantly reduces human intervention, process variability, and resource consumption.

graph LR
    A[MSC Culture Batch] --> F(Feed Pump);
    F --> B(Centrifugal Filter System);
    B -- Purified MSCs --> C[Product Collection];
    B -- Filtrate --> D[Waste];

    subgraph AI Control Loop
        Sensors(Optical, Biochemical, Flow) -- Real-time Data --> AI_Engine(AI Optimization Algorithm);
        AI_Engine -- Predicted Optimal Parameters --> Actuators(Pump Speeds, Valves, RPM);
        Actuators --> F, B;
        AI_Engine -- Quality Metrics --> Log(Blockchain/LIMS);
    end

Derivative 2.5: The "Inverse" or Failure Mode – Automated Fail-Safe Centrifugal Filtration System

Enabling Description: An hMSC purification system employing centrifugal filtration that incorporates an automated fail-safe mechanism designed to prevent the release of sub-standard or compromised product. The system continuously monitors critical process parameters (e.g., membrane integrity via pressure decay, real-time BSA levels via spectroscopic analysis, cell viability via automated image analysis). If any parameter deviates beyond predefined safety thresholds (e.g., BSA > 15 μg/mL, viability < 80%, D90 of aggregates > 150 μm, or membrane breach), the system automatically triggers a controlled shutdown. This involves diverting the product stream to a quarantine reservoir, initiating a thorough system sterilization cycle, and generating a detailed fault report. This prevents the downstream processing or administration of potentially harmful MSC compositions, ensuring patient safety even in the event of component failure or operational error.

stateDiagram-v2
    state ActivePurification {
        [*] --> Initializing
        Initializing --> Running: Parameters nominal
        Running --> Monitoring: Continuous
        Monitoring --> Running: Parameters nominal
        Monitoring --> CriticalAlert: Deviation detected (e.g., BSA, Viability, D90, Membrane integrity)
    }
    state CriticalAlert {
        CriticalAlert --> DivertProduct: Isolate compromised batch
        DivertProduct --> SystemShutdown: Halt operation
        SystemShutdown --> SterilizationCycle: Clean system
        SterilizationCycle --> ReportGeneration: Log fault details
        ReportGeneration --> [*]: System safe, ready for reset
    }

---

Core Concept 3: Dosing and Selection based on Safety Thresholds

(Deriving from claims like 29, 30, focusing on establishing and using IV safety thresholds for xenogeneic proteins.)

Derivative 3.1: Material & Component Substitution – Threshold Determination for Novel Viral Inactivation Agents

Enabling Description: A method for selecting a cellular therapy product for administration, where the non-human protein in question is a residual component of a novel chemical viral inactivation agent (e.g., a proprietary benzonase derivative) used during upstream cell processing, rather than BSA. The method involves measuring the amount of this specific non-human viral inactivation agent in the human mesenchymal stem cell (hMSC) suspension. A safety threshold is established by administering varying doses of the agent (or a suitable surrogate with higher immunogenicity) to an animal model via intravenous route, and determining the No Observed Adverse Effect Level (NOAEL) or Minimum Immunogenic Dose (MID). A cell suspension is then selected for patient administration if the amount of the viral inactivation agent is less than the empirically determined threshold, e.g., less than 100 μg per kilogram of patient body weight. This ensures patient safety from potential immunogenic or toxic reactions to novel processing reagents.

graph TD
    A[hMSC Suspension Processed with Viral Inactivation Agent] --> B{Measure Residual Agent Concentration};
    B --> C{Animal Model Study (IV Admin of Agent)};
    C -- Determine NOAEL/MID (e.g., 100µg/kg) --> D[Establish Safety Threshold];
    D --> E{Compare Measured Residual vs. Threshold};
    E -- Below Threshold --> F[Select for Patient Administration];
    E -- Above Threshold --> G[Reject Batch / Repurify];

Derivative 3.2: Operational Parameter Expansion – Patient-Specific, Real-Time Adaptive Dosing

Enabling Description: A method for treating or preventing a disease using a purified MSC composition, where the administered dose of MSCs and the associated xenogeneic protein load are dynamically adjusted in real-time based on the individual patient's physiological response and current immunological status. Prior to administration, a baseline patient assessment includes genotyping for immunocompatibility markers (e.g., HLA alleles), quantification of pre-existing antibodies against xenogeneic proteins (e.g., anti-BSA IgE/IgG), and inflammatory cytokine profiles. During intravenous administration of the MSC composition (containing < 55 μg/mL residual BSA), continuous monitoring of acute inflammatory markers (e.g., C-reactive protein, cytokine storm indicators) and vital signs occurs. An AI-driven algorithm integrates this real-time data to adaptively control the infusion rate or total dose administered, ensuring that the cumulative xenogeneic protein exposure remains below a personalized, dynamically calculated threshold (e.g., adjusted from the baseline 500 μg BSA/kg to 250 μg BSA/kg for a highly sensitized patient, or increased for a tolerant patient), thus maximizing efficacy while minimizing adverse reactions.

graph TD
    A[Purified MSC Composition (<55µg/mL BSA)] --> B{Patient Pre-Assessment};
    B -- Immunological Profile, Genotype --> C[Personalized Threshold Algorithm];
    C --> D{Initiate IV Infusion};
    D --> E{Real-time Patient Monitoring (Inflammation, Vitals)};
    E -- Data Stream --> C;
    C -- Adaptive Dose Adjustment --> D;
    D -- Cumulative Xenogeneic Load < Personalized Threshold --> F[Successful Treatment];
    C -- Threshold Exceeded / Adverse Reaction --> G[Halt Infusion / Emergency Protocol];

Derivative 3.3: Cross-Domain Application – Dose Selection for Immunotherapy in Companion Animals

Enabling Description: A method for selecting a cellular therapy product containing non-human proteins (e.g., canine serum components in a feline MSC preparation, or vice versa, for veterinary applications) for administration to a companion animal (e.g., dog, cat, horse). This method addresses the species-specific immunological considerations in veterinary medicine. It comprises: (a) measuring the amount of at least one non-species-specific protein (e.g., feline albumin when administering canine MSCs expanded in feline serum) in a cell suspension; and (b) selecting a cell suspension for administration where the amount of said non-species-specific protein is less than about 200 μg per kilogram of the recipient animal's body weight. This threshold is established through species-specific dose escalation studies in veterinary models, taking into account common sensitivities in companion animals. This ensures safety for allogeneic or xenogeneic cellular therapies in veterinary oncology or orthopedic applications.

graph TD
    A[Cultured Animal MSCs + Non-Species Serum] --> B{Measure Non-Species Protein};
    B --> C{Species-Specific Animal Model Study};
    C -- Determine Vet-NOAEL (e.g., 200µg/kg) --> D[Establish Vet Safety Threshold];
    D --> E{Compare Measured Residual vs. Vet Threshold};
    E -- Below Threshold --> F[Select for Companion Animal Treatment];
    E -- Above Threshold --> G[Reject Batch / Repurify for Vet Use];

---

Combination Prior Art Scenarios

These scenarios combine aspects of US patent 8637004 with existing open-source standards, demonstrating how the patent's core ideas could be implemented or extended using publicly available technology, thereby contributing to the prior art.

Combination Prior Art 1: Centrifugal Filtration with Open-Source Bioreactor Control Systems

Enabling Description: A method for manufacturing purified hMSC compositions where the entire upstream cell culture expansion and downstream centrifugal filtration purification process are integrated and controlled by an open-source bioreactor control system (e.g., a customized version of the "OpenCell" project or "Open-Bioreactor"). The open-source software manages parameters such as media feeding, gas exchange, temperature, and agitation during cell expansion. Upon reaching harvest density, the system automatically triggers the transfer of cells to a centrifugal filtration unit. The purification module, built using readily available components, operates under control logic provided by the same open-source platform, adjusting wash buffer flow rates, recirculation rates, and filter transmembrane pressures. This open-source integrated system ensures that the recovered hMSCs meet the target residual BSA levels (e.g., < 55 μg/mL) and aggregate D90 (< 150 μm), and all process data (e.g., purification yields, BSA reduction factors) are logged and timestamped within the open-source database.

graph TD
    A[Open-Source Bioreactor] --> B{Harvest Valve};
    B --> C[Open-Source Centrifugal Filter Unit];
    C -- Filtrate --> D[Waste Collection];
    C -- Purified MSCs --> E[Product Collection];
    A -- Control Data --> F(OpenCell Control Software);
    C -- Process Data --> F;
    F -- Logged Data --> G[Open-Source Database];

Combination Prior Art 2: Aggregate D90 Analysis with Open-Source Flow Cytometry Data Standards

Enabling Description: A method for quality control and characterization of purified mesenchymal stem cell (MSC) compositions, leveraging open-source flow cytometry data standards. After purification (e.g., via centrifugal filtration as described in US8637004 to achieve aggregate D90 < 150 μm and MSC D90 18-30 μm), an aliquot of the MSC composition is analyzed using a flow cytometer. The flow cytometer is configured to detect and size individual MSCs and any aggregates present. The resulting raw data (e.g., forward scatter and side scatter parameters, cell counts, aggregate counts) are stored in the universally adopted open-source Flow Cytometry Standard (FCS) file format (e.g., FCS 3.1). This standard format allows for interoperability and subsequent analysis using various open-source bioinformatics tools (e.g., FlowJo, Cytospec, Bioconductor packages in R) to accurately quantify the D90 of aggregates and individual MSCs, verify viability, and compare batch consistency across different laboratories or instruments, without proprietary software restrictions.

sequenceDiagram
    participant M as MSC Purification (e.g., CF)
    participant S as Sample Collection
    participant FC as Flow Cytometer
    participant D as Data Storage
    participant A as Open-Source Analysis Software

    M->S: Collect Purified MSC Sample
    S->FC: Load Sample
    FC->FC: Perform Light Scatter & Cell Count Analysis
    FC->D: Export Raw Data (FCS 3.1 Format)
    D->A: Import FCS Data
    A->A: Calculate Aggregate D90, MSC D90, Viability
    A->A: Generate Quality Control Report
    A->>M: Feedback on Batch Quality

Combination Prior Art 3: BSA Threshold Compliance with Open-Source LIMS Integration

Enabling Description: A method for ensuring compliance with residual bovine serum albumin (BSA) thresholds in purified human mesenchymal stem cell (hMSC) compositions by integrating the purification process and analytical testing with an open-source Laboratory Information Management System (LIMS). After culturing and centrifugal filtration purification, the hMSC composition's residual BSA is quantified using a validated ELISA assay. The BSA concentration data (e.g., < 55 μg/mL as claimed in US8637004) is automatically input into a customized open-source LIMS (e.g., "OpenLIMS" or a community-driven LIMS solution). The LIMS cross-references this data with predefined safety thresholds and batch-specific parameters, such as initial FBS concentration and purification efficiency. The system automates batch release decisions, flags out-of-specification results, generates audit trails, and manages sample tracking throughout the manufacturing workflow, providing transparent and verifiable documentation for regulatory submissions.

flowchart TD
    A[MSC Culture] --> B{Centrifugal Filtration};
    B --> C[Purified MSC Sample];
    C --> D{Residual BSA ELISA};
    D -- BSA Concentration Data --> E[Open-Source LIMS];
    E -- Reference Threshold (<55µg/mL) --> F{Decision Logic};
    F -- Compliant --> G[Batch Release];
    F -- Non-Compliant --> H[Quarantine / Re-process];
    E --> I[Audit Trail / Reporting];